In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


EU publishes updated cosmetics regs

This article was originally published in The Rose Sheet

Executive Summary

1Revamped cosmetics regulations from the European Commission appear in the Dec. 22 edition of its Official Journal. New framework will enter into force Jan. 11, gradually replacing outmoded requirements under the European Cosmetics Directive launched in 1976. A number of changes concerning the manufacture, import, testing and marketing of cosmetics have been introduced (2"The Rose Sheet" Nov. 16, 2009). The "crucial" legislation "will continue to provide a stable regulatory environment for cosmetics companies and keep the high expectations on consumer safety," according to the European Cosmetics Association (Colipa)

You may also be interested in...

France Advances Phthalate & Paraben Ban With National Assembly Vote

Suspected endocrine disruptors phthalates and parabens could be banned in consumer products in France following a narrow vote in the country’s National Assembly.

New EU Cosmetics Regs Expected Before Year-End; Focus Is Accountability

New cosmetics regulations under the recast directive are expected to publish in the Official Journal of the European Union by year-end, according to Darren Abrahams, a barrister (lawyer), in the Brussels office of Steptoe & Johnson LLP

FDA Slacking In NDI Notification Enforcement; COVID-19 'Is Not An Excuse’ – NPA

In a statement submitted to the Senate Finance Committee, Natural Products Association CEO Dan Fabricant suggests two ways of improving compliance with new dietary ingredient notification requirements at negligible expense to the US FDA.




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts